Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.75 |
| ▸ | GLA | P06280 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | MGLL | Q99685 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2436689 | 0.92 | HPGD (0.65) | TSHRGLAKMT2AMGLLMAPT | |
| SCHEMBL14409571 | 0.89 | TSHR (0.70) | TSHRGLAKMT2AGAAALDH1A1 | |
| SCHEMBL4172039 | 0.86 | TSHR (0.67) | TSHRGLAKMT2AGAAALDH1A1 | |
| SCHEMBL3339277 | 0.86 | TSHR (0.67) | TSHRGLAKMT2AGAAALDH1A1 | |
| SCHEMBL6973124 | 0.86 | GAA (0.73) | TSHRGLAKMT2AGAAALDH1A1 | |
| SCHEMBL4598393 | 0.85 | TSHR (0.66) | TSHRGLAKMT2AGAAALDH1A1 | |
| SCHEMBL315088 | 0.85 | TSHR (0.72) | TSHRGLAKMT2AMGLLGAA | |
| SCHEMBL6271671 | 0.85 | HPGD (0.77) | TSHRGLAKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL6504430 | 0.84 | KMT2A (0.74) | TSHRGLAKMT2AGAAALDH1A1 | |
| SCHEMBL4468382 | 0.83 | GAA (0.64) | TSHRGLAKMT2AMGLLGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| EP-1701959-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | Pfizer Limited (GB) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005063754-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-07-14 | — | — | WO | disclosed |
| US-20050154024-A1 | Compounds useful in therapy | PFIZER INC | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154024-A1 | Compounds useful in therapy | PTGER4, PTGER3, ALOX5 | TSHR 577/4885GLA 3637/4885KMT2A 3968/4885 |
| US-20100317652-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | TSHR 1559/4885GLA 1669/4885KMT2A 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.